Correct Answer: D. Rifampicin induces OCP metabolism and cause failure
Rifampicin is a potent inducer of hepatic cytochrome P450 enzymes, particularly CYP3A4, which is responsible for metabolizing ethinylestradiol and progestins in oral contraceptive pills. When rifampicin is co-administered with OCPs, it dramatically increases the hepatic metabolism of contraceptive steroids, leading to significantly reduced plasma concentrations of these hormones. This results in subtherapeutic levels of OCP, compromising contraceptive efficacy and increasing the risk of unintended pregnancy. The mechanism is enzyme induction, not inhibition. This is a well-established drug interaction documented in Indian guidelines (RNTCP/NTEP) and clinical practice. Patients on antitubercular therapy containing rifampicin must be counseled to use additional barrier methods (condoms) or switch to non-hormonal contraception (copper-T, barrier methods) during TB treatment and for at least 4 weeks after completing rifampicin therapy. This is a critical counseling point in Indian TB clinics and reproductive health settings, as unintended pregnancies in TB patients on ATT carry significant maternal and fetal risks.
Why the other options are wrong
A. Failure — This option is incomplete and vague. While it correctly identifies that OCP failure occurs, it does not explain the mechanism—why failure happens. NBE expects students to identify the specific pharmacological mechanism (enzyme induction by rifampicin) rather than just naming the outcome. A complete answer must include both the mechanism and the consequence. B. Rifampicin decreases OCP metabolism — This is factually incorrect and represents a common misconception. Rifampicin is a potent enzyme inducer, not an inhibitor. It increases (not decreases) OCP metabolism, leading to lower hormone levels. This trap may catch students who confuse rifampicin's action with other drugs like ketoconazole or erythromycin, which inhibit metabolism. The opposite mechanism is stated here. C. Teratogenic — This is incorrect. While antitubercular drugs like streptomycin and thiacetazone are teratogenic, rifampicin itself is not considered a major teratogen and is actually used in pregnant TB patients. The advice for barrier contraception is not because ATT is teratogenic, but because rifampicin reduces OCP efficacy. Teratogenicity is a separate concern unrelated to this drug interaction.
High-Yield Facts
- Rifampicin is a potent CYP3A4 inducer that increases metabolism of ethinylestradiol and progestins, reducing OCP plasma levels by 40–50%.
- OCP failure risk increases significantly when co-administered with rifampicin; barrier contraception or non-hormonal methods are mandatory during TB treatment.
- Enzyme induction by rifampicin is the mechanism; it is NOT enzyme inhibition (which would increase hormone levels).
- Duration of interaction: Barrier methods should be continued for at least 4 weeks after completing rifampicin, as enzyme induction persists.
- Other enzyme inducers in ATT (isoniazid, pyrazinamide) have minimal effect on OCP; rifampicin is the primary culprit.
- Indian TB guidelines (RNTCP/NTEP) recommend counseling all women of reproductive age on TB treatment about contraceptive failure risk.
Mnemonics
RIF = Rapid Induction Failure Rifampicin → Rapid enzyme induction → Faster OCP metabolism → Failure of contraception. Use this when counseling TB patients on OCPs. CYPE (Cytochrome P450 Enzyme) Rifampicin induces CYP3A4 → Estrogen/Progestin metabolized faster → Plasma levels drop → Contraceptive failure. Remember: induction = faster breakdown = lower levels = failure.
NBE Trap
NBE pairs "failure" (option A) with incomplete reasoning to trap students who know OCP fails but cannot articulate the mechanism. The distractor "decreases OCP metabolism" (option B) reverses the actual mechanism, catching those who confuse rifampicin with enzyme inhibitors like ketoconazole.
Clinical Pearl
In Indian TB clinics, unintended pregnancies in women on ATT are a common complication with poor maternal and fetal outcomes. Counseling women of reproductive age about rifampicin-OCP interaction and offering barrier methods or copper-T insertion before starting ATT is a standard of care that prevents both contraceptive failure and adverse pregnancy outcomes in TB patients.
_Reference: KD Tripathi Pharmacology Ch. 63 (Antitubercular Drugs); Harrison Principles of Internal Medicine Ch. 158 (Tuberculosis); Robbins Pathologic Basis of Disease Ch. 8 (Drug-induced injury)_